Preventing Type II Diabetes Mellitus

Journal of Clinical Pharmacology

Volumn 44, Issue 4, 2004, Pages 406-413

  Prisant, L Michael ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Controlled trials; Diabetes mellitus; Glucose intolerance; Lifestyle; Prevention; Review

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GLUCOSE; HYDROCHLOROTHIAZIDE; LOSARTAN; MEDROXYPROGESTERONE ACETATE; METFORMIN; NATEGLINIDE; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VALSARTAN;

BLINDNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FAILURE; LEG AMPUTATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; SIDE EFFECT; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ESTROGEN REPLACEMENT THERAPY; EXERCISE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS; WEIGHT LOSS;

EID: 1642369337     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004263018     Document Type: Conference Paper

References (43)

1. Mokdad AH, Ford ES, Bowman BA, et al: Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-1283.
2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
3. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
4. Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-699.
5. Henry P, Thomas F, Benetos A, Guize L: Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002;40:458-463.
6. Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001;24:447-453.
7. The prevention or delay of type 2 diabetes. Diabetes Care 2002;25:742-749.
8. Hu FB, Sigal RJ, Rich-Edwards JW, et al: Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 1999;282:1433-1439.
9. Hu FB, Manson JE, Stampfer MJ, et al: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-797.
10. Jarrett RJ, Keen H, Fuller JH, McCartney M: Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia 1979;16:25-30.
11. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G: Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-49.
12. Keen H, Jarrett RJ, McCartney P: The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 1982;22:73-78.
13. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991;34:891-898.
14. Pan XR, Li GW, Hu YH, et al: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.
15. Tuomilehto J, Lindstrom J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
16. Hammersley MS, Meyer LC, Morris RJ, Manley SE, Turner RC, Holman RR: The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial. Metabolism 1997;46:44-49.
17. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC: The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997;46:50-55.
18. Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR: The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997;46:56-60.
19. Dyson PA, Mehta Z, Hammersley M, Holman RR: Reinforced healthy living advice over six years does not delay progression to diabetes. Diabetologia 2000;43(Suppl. 1):A114.
20. Herlihy OM, Morris RJ, Holman RR: Sulphonylurea therapy over six years does not delay progression to diabetes. Diabetologia 2000;43(Suppl. 1):A73.
21. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000;23:1619-1629.
22. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
23. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA: TRIPOD (Troglitazone in the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217-231.
24. Buchanan TA, Xiang AH, Peters RK, et al: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803.
25. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998;21:1720-1725.
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077.
27. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494.
28. Torgerson JS, Arlinger K, Kappi M, Sjostrom L: Principles for enhanced recruitment of subjects in a large clinical trial: the XENDOS (XENical in the Prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials 2001;22:515-525.
29. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.
30. Heymsfield SB, Segal KR, Hauptman J, et al: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-1326.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
32. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259.
33. Yusuf S, Gerstein H, Hoogwerf B, et al: Ramipril and the development of diabetes. JAMA 2001;286:1882-1885.
34. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
35. Lindholm LH, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.
36. Freeman DJ, Norrie J, Sattar N, et al: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362.
37. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
38. Kanaya AM, Herrington D, Vittinghoff E, et al: Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9.
39. Wilson PW: Lower diabetes risk with hormone replacement therapy: an encore for estrogen? Ann Intern Med 2003;138:69-70.
40. Holman RR: Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998;40(Suppl.):S21-S25.
41. Holman RR, North BV, Tunbridge FK: Possible prevention of type 2 diabetes with acarbose or metformin. Diabetes 2000;49(Suppl. 1): A111.
42. Gerstein HC: Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002;18(Suppl. 3):S82-S85.
43. Nateglinide and valsartan in impaired glucose tolerance outcomes research: rationale and design of the NAVIGATOR trial. Diabetes 2002;51(Suppl. 2):A116.